We are live on ! Find out more
ICU icon

SeaStar Medical

3.94 USD
+0.38
10.67%
At close Updated Sep 30, 4:00 PM EDT
Pre-market
After hours
3.95
+0.01
0.25%
1 day
10.67%
5 days
14.2%
1 month
25.88%
3 months
7.36%
6 months
8.84%
Year to date
49.81%
1 year
-30.88%
5 years
-99.84%
10 years
-99.84%
 

About: SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Employees: 17

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
1 day ago
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE ® , an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Neutral
GlobeNewsWire
6 days ago
SeaStar Medical Congratulates H. David Humes, M.D.
Prestigious honor recognizes Dr. Humes' pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE ® for critically ill pediatric patients with acute kidney injury (AKI)
SeaStar Medical Congratulates H. David Humes, M.D.
Neutral
GlobeNewsWire
20 days ago
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City.
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
Neutral
Seeking Alpha
1 month ago
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Added 3 top-rated children's hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its second quarter financial results after market close on Wednesday, August 12, 2026, and host a webcast and conference call to discuss its financial results and business progress.
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
Neutral
GlobeNewsWire
2 months ago
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that it is a proud sponsor of key initiatives to advance the treatment of pediatric patients with acute kidney injury (AKI). AKI is a major driver of critical illness, prolonged hospital stays, and high mortality rates.
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
Neutral
GlobeNewsWire
3 months ago
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Enables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Neutral
GlobeNewsWire
3 months ago
SeaStar Medical to Present at Upcoming Investor Summit Conference
DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Virtual Investor Summit Conference on Wednesday, June 24th at 10:30 am Eastern Time.
SeaStar Medical to Present at Upcoming Investor Summit Conference
Neutral
Seeking Alpha
4 months ago
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™